Maze Therapeutics (MAZE) Stock Price, News & Analysis

Company Overview

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues. By reducing glycogen production, the therapy is intended to address a central biological driver of the disease. The company is also advancing additional discovery and development programs based on genetically validated targets.

Founded in 2018 and headquartered in San Diego, California, Maze Therapeutics serves the global biopharmaceutical market through research and clinical development activities. The company is led by Jason Coloma, Ph.D., who serves as president and chief executive officer.

Key Stats

• Today's Range: $24.36 to $25.99
• 50-Day Range: $24.58 to $32.84
• 52-Week Range: $22.01 to $53.65
• Volume: 1.05 million shs
• Average Volume: 390,577 shs
• Market Capitalization: $1.37 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $66.00
• Consensus Rating: Buy

Maze Therapeutics Stock Analysis - MarketRank™

Maze Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 561st out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Maze Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 3 strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Maze Therapeutics has a consensus price target of $66.00, representing about 168.3% upside from its current price of $24.60.

Amount of Analyst Coverage

Maze Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Maze Therapeutics are expected to decrease in the coming year, from ($2.72) to ($3.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Maze Therapeutics is -9.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Maze Therapeutics is -9.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Maze Therapeutics has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.25% of the float of Maze Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Maze Therapeutics has a short interest ratio ("days to cover") of 16.05, which indicates bearish sentiment.

Change versus previous month

Short interest in Maze Therapeutics has recently decreased by 1.18%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Maze Therapeutics does not currently pay a dividend.

Dividend Growth

Maze Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.45

News Sentiment

Maze Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Maze Therapeutics this week, compared to 5 articles on an average week.

Search Interest

2 people have searched for MAZE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Maze Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Maze Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,989,040.00 in company stock.

Percentage Held by Insiders

5.30% of the stock of Maze Therapeutics is held by insiders.

Percentage Held by Institutions

Maze Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/12/2026
• H.C. Wainwright 28th Annual Global Investment Conference: 9/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MAZE
• Previous Symbol: NASDAQ:MAZE
• CIK: 1842295
• Web: mazetx.com
• Phone: (650) 850-5070
• Fax: N/A
• Employees: 141
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Maze Therapeutics: $66.00
• High Price Target: $110.00
• Low Price Target: $46.00
• Potential Upside/Downside: +168.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.08
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$131.12 million
• Net Margins: N/A
• Pretax Margin: -667.95%
• Return on Equity: -34.94%
• Return on Assets: -30.18%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 18.31
• Quick Ratio: 18.31

Sales & Book Value

• Annual Sales: $167.50 million
• Price / Sales: 8.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.38 per share
• Price / Book: 3.33

Miscellaneous

• Outstanding Shares: 55,550,000
• Free Float: 52,605,000
• Market Cap: $1.37 billion
• Optionable: N/A
• Beta: 2.17